View Clinical Trial (Medical Research Study)
A Multicenter, Randomized Study of the Efficacy and Safety of NVC-422 Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis
| City: |
|
Hazard |
| State: |
|
Kentucky |
| Zip Code: |
|
41701 |
| Conditions: |
|
Adenoviral Conjunctivitis |
| Purpose: |
|
The purpose of this study is to evaluate the clinical and microbiological efficacy and
safety of NVC-422 compared to vehicle for adenoviral conjunctivitis. Adults and children one
year of age and older with adenoviral conjunctivitis in at least one eye may be eligible.
Subjects will be randomly assigned to receive either NVC-422 or Vehicle. Six visits will be
required for this study.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Signs and symptoms of viral conjunctivitis in at least one eye for 3 days or less
- Bulbar conjunctival injection
- Other inclusion criteria per protocol
Exclusion Criteria:
- Presence of subepithelial infiltrates (SEIs) at the Day 1 visit in either eye
- A suspected bacterial, fungal, herpes, Chlamydia or Acanthamoeba co-infection, based
on clinical observation
- Other exclusion criteria per protocol
|
| NCT ID: |
|
NCT01532336 |
| Primary Contact: |
|
Study Director
David Stroman, Ph.D.
NovaBay Pharmaceuticals, Inc.
Susan M Iovino, BSMT(ASCP)
Phone: 510-899-8853
Email: siovino@novabaypharma.com
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Hazard, Kentucky 41701
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 17, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|